RFS for nivolumab versus placebo and nivolumab versus ipilimumab
death, melanoma
RECURRENCE, MELANOMA
In the pooled population, patients in the nivolumab arm showed an improvement in RFS compared with those in the placebo arm (HR for recurrence or death: 0.49; 95% CI 0.39–0.61) and ipilimumab arm (HR for recurrence or death: 0.69; 95% CI 0.56–0.85; Fig. Weighted RFS in the pooled study population by treatment arm. Shaded areas indicate 95% CIs. NNT with adjuvant nivolumab versus placebo and nivolumab versus ipilimumab to obtain one additional recurrence-free survivor at 12, 24, 36, and 48 months among patients with stage IIIB-C melanoma. NNT was calculated as the reciprocal of the absolute risk reduction in RFS and represented the number of patients needed to be treated with the intervention versus its comparator to obtain one additional recurrence-free survivor. At 12 months, the NNT for one additional recurrence-free survivor was 4.1 (95% CI 3.1–6.1) for nivolumab versus placebo, and 8.3 (95% CI 5.3–19.2) for nivolumab versus ipilimumab (Fig. 